Equities

Craneware PLC

CRWRF:PNK

Craneware PLC

Actions
TechnologySoftware & Computer Services
  • Price (USD)36.75
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta1.2694
Data delayed at least 15 minutes.
More ▼

Profile data is unavailable for this security.

About the company

Craneware plc is a United Kingdom-based company, which is engaged in the development, licensing and ongoing support of computer software for the United States healthcare industry. The Company's Value Cycle Solutions span over five product families, which include Patient Engagement, Charge Capture & Pricing, Coding Integrity, Cost Analytics, and Revenue Collection & Retention. Its Patient Engagement solutions include InSight Medical Necessity, Trisus Patient Payment and Patient Charge Estimator. The Charge Capture & Pricing solutions include Chargemaster Toolkit Discovery Viewer; Physician Revenue Toolkit, Physician Management Toolkit and Physician Revenue Toolkit-Corporate; Pricing Analyzer; Reference Plus; Pharmacy ChargeLink; Supplies ChargeLink, and Supporting Modules. Its Coding Integrity solutions include Trisus Claims Informatics and Bill Analyzer. Its Revenue Recovery & Retention solutions include InSight Audit and InSight Denials. It also offers professional services.

  • Revenue in GBP (TTM)57.02m
  • Net income in GBP13.76m
  • Incorporated1999
  • Employees295.00
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.